WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002028352) A MODULATOR OF ANTIESTROGEN PHARMACOLOGY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/028352    International Application No.:    PCT/US2001/031271
Publication Date: 11.04.2002 International Filing Date: 05.10.2001
IPC:
A61K 38/00 (2006.01), C07K 14/47 (2006.01)
Applicants: CASE WESTERN RESERVE UNIVERSITY [US/US]; 10900 Euclid Avenue, Cleveland, OH 44106 (US) (For All Designated States Except US).
MONTANO, Monica [US/US]; (US) (For US Only).
SUTTON, Amelia [US/US]; (US) (For US Only)
Inventors: MONTANO, Monica; (US).
SUTTON, Amelia; (US)
Agent: DOCHERTY, Pamela, A.; Calfee, Halter & Griswold LLP, 1400 McDonald Investment Center, 800 Superior Avenue, Cleveland, OH 44114 (US)
Priority Data:
60/238,190 05.10.2000 US
Title (EN) A MODULATOR OF ANTIESTROGEN PHARMACOLOGY
(FR) MODULATEUR DE PHARMACOLOGIE ANTIOESTROGENIQUE
Abstract: front page image
(EN)A protein, designated ERCoA3 is provided. The ERCoA3 protein interacts with the estrogen receptor and the progesterone receptor and causes activation of these receptors is provided. Also provided are polynucleotides which encode ERCoA3 or block translation of the mRNA which encodes ERCoA3. Antibiodies that bind to one or more epitopes in the human ERCoA3 protein are provided. The present invention also relates to methods of inhibiting or reducing tamoxifen or estrogen induced proliferation of cancer cells, particularly breast cancer cells, endometrial cancer cells and uterine cancer cells. The method comprises reducing the activity or levels of ERCoA3 in such.
(FR)L'invention concerne une protéine, appelée ERCoA3, qui interagit avec le récepteur de l'oestrogène et le récepteur du progestérone afin de les activer. L'invention concerne également des polynucléotides codant ERCoA3, ou une traduction séquencée de l'ARNm codant ERCoA3, ainsi que des anticorps qui se lient à un ou plusieurs épitopes dans la protéine ERCoA3 humaine. L'invention concerne en outre des méthodes qui inhibent ou réduisent la prolifération de cellules cancéreures induite par tamoxifène ou oestrogène, en particulier les cellules cancéreuses du sein, les cellules cancéreuses de l'endomètre et les cellules cancéreuses de l'utérus. La méthode consiste à diminuer l'activité ou les niveaux d'ERCoA3.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)